Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
4.280
+0.100 (2.39%)
At close: Nov 18, 2026, 4:00 PM EST
4.440
+0.160 (3.74%)
After-hours: Nov 18, 2026, 6:30 PM EST
Lexaria Bioscience Revenue
Lexaria Bioscience had revenue of $194.00K in the twelve months ending May 31, 2026, down -68.50% year-over-year. In the fiscal year ending August 31, 2025, Lexaria Bioscience had annual revenue of $705.92K with 52.05% growth. That makes Lexaria Bioscience the 45,546th largest company in the world by revenue and 6,641st in the United States.
Revenue (ttm)
$194.00K
Revenue Growth
-68.50%
P/S Ratio
46.47
Revenue / Employee
$27,714
Employees
7
Market Cap
9.02M
Revenue by Segment
- Intellectual Property Licensing 696.00K 98.6%
- B2B Product 9.92K 1.4%
Fiscal year ended Aug 31, 2025 See the full Lexaria Bioscience breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | 705.92K | 241.65K | 52.05% |
| Aug 31, 2024 | 464.28K | 238.07K | 105.24% |
| Aug 31, 2023 | 226.21K | -29.19K | -11.43% |
| Aug 31, 2022 | 255.40K | -467.34K | -64.66% |
| Aug 31, 2021 | 722.74K | 407.95K | 129.59% |
| Aug 31, 2020 | 314.79K | 92.18K | 41.41% |
| Aug 31, 2019 | 222.61K | -210.68K | -48.62% |
| Aug 31, 2018 | 433.29K | 369.65K | 580.85% |
| Aug 31, 2017 | 63.64K | 22.92K | 56.29% |
| Aug 31, 2016 | 40.72K | 26.02K | 176.96% |
| Aug 31, 2015 | 14.70K | - | - |
| Aug 31, 2014 | - | - | - |
| Oct 31, 2013 | 1.10M | -260.31K | -19.17% |
| Oct 31, 2012 | 1.36M | 224.00K | 19.76% |
| Oct 31, 2011 | 1.13M | 771.30K | 212.79% |
| Oct 31, 2010 | 362.47K | -59.48K | -14.10% |
| Oct 31, 2009 | 421.96K | -478.83K | -53.16% |
| Oct 31, 2008 | 900.79K | 647.64K | 255.83% |
| Oct 31, 2007 | 253.15K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aligos Therapeutics | 33.65M |
| Radiopharm Theranostics | 8.90M |
| TScan Therapeutics | 5.19M |
| BioLineRx | 1.39M |
| CytoMed Therapeutics | 609.73K |
| Lisata Therapeutics | 100.00K |
LEXX News
- 14 days ago - Lexaria Bioscience enters new pharmaceutical agreement for DehydraTECH - TheFly
- 14 days ago - Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH - TheNewswire
- 21 days ago - Lexaria Bioscience announces 70th patent award - TheFly
- 21 days ago - Lexaria Celebrates its 70th Patent Award - TheNewswire
- 4 weeks ago - Lexaria Bioscience reaches full enrollment in GLP-1-H26-7 study - TheFly
- 4 weeks ago - Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule - TheNewswire
- 4 weeks ago - Lexaria Bioscience announces results from animal study GLP-1-A26-1 - TheFly
- 4 weeks ago - Lexaria Announces Results from Animal Study GLP-1-A26-1 - Accesswire